Emerging therapies in the medical management of thyroid eye disease
IntroductionThyroid eye disease (TED) is an immune-mediated disorder associated with a heterogenous array of manifestations that may unfavorably impact vision and quality of life. As understanding of this entity’s complex pathogenesis has evolved, so have therapies with novel molecular targets offer...
Main Authors: | Alisha Kamboj, Andrew R. Harrison, Ali Mokhtarzadeh |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Ophthalmology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fopht.2023.1295902/full |
Similar Items
-
The association of race with thyroid eye disease presentation and outcomes
by: Diane Wang, et al.
Published: (2024-01-01) -
Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01) -
Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker
by: Yihan Zhou, et al.
Published: (2023-06-01) -
Megalin Orchestrates FcRn Endocytosis and Trafficking
by: Eileen Dahlke, et al.
Published: (2022-12-01) -
Incidence of the postpartum diagnosis of thyroid eye disease in relation to thyroid function in Graves’ disease
by: Nami Suzuki, et al.
Published: (2025-01-01)